Business

Novo to advance CagriSema despite missing key endpoint against Lilly in obesity trial

Patients taking CagriSema lost 23% of their body weight under the efficacy analysis, compared with 25.5% for tirzepatide

Economist AdminEconomist Admin
Novo to advance CagriSema despite missing key endpoint against Lilly in obesity trial
Patients taking CagriSema lost 23% of their body weight under the efficacy analysis, compared with 25.5% for tirzepatide
Read More

Tags:

Previous Article

Cost of living reality in 2026: Where does money flow faster -- India or US?

Next Article

Shashi Tharoor: 'I Don't Know What Difference It Makes' To Rename Kerala To Keralam

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Economist Admin
Economist Admin Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.

Related Posts

Delhi High Court dismisses Sameer Wankhede's defamation plea against Aryan Khan's 'The B***ds of Bollywood'

Delhi High Court dismisses Sameer Wankhede's defamation...

Economist Admin

India has secured a better trade deal with the US than competitors: Goyal

India has secured a better trade deal with the US than ...

Economist Admin

Air India welcomes first Boeing 787-9 Dreamliner after Tata Group's takeover. Check details

Air India welcomes first Boeing 787-9 Dreamliner after ...

Economist Admin